INGN logo

Inogen, Inc. Stock Price

NasdaqGS:INGN Community·US$146.0m Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

INGN Share Price Performance

US$5.37
-2.73 (-33.70%)
US$12.67
Fair Value
US$5.37
-2.73 (-33.70%)
57.6% undervalued intrinsic discount
US$12.67
Fair Value
Price US$5.37
AnalystConsensusTarget US$12.67
AnalystLowTarget US$12.00
AnalystHighTarget US$14.00

INGN Community Narratives

·
Fair Value US$12.67 57.6% undervalued intrinsic discount

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

0users have liked this narrative
2users have commented on this narrative
6users have followed this narrative
·
Fair Value US$12 55.3% undervalued intrinsic discount

Pricing Pressures And Rivals Will Erode Portable Oxygen Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$14 61.6% undervalued intrinsic discount

Aging Global Population And At-Home Care Will Boost Market Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$12
55.3% undervalued intrinsic discount
Profit Margin
12.11%
Future PE
7.96x
Price in 2029
US$14.86
US$14
61.6% undervalued intrinsic discount
Profit Margin
12.32%
Future PE
11.21x
Price in 2028
US$14.54

Trending Discussion

No trending discussion available.

Updated Narratives

INGN logo

INGN: Bullish Initiation And New CFO Will Support Future Upside

Fair Value: US$12 55.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INGN logo

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Fair Value: US$12.67 57.6% undervalued intrinsic discount
6 users have set this as their fair value
2 users have commented on this narrative
0 users have liked this narrative
INGN logo

Aging Global Population And At-Home Care Will Boost Market Demand

Fair Value: US$14 61.6% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

1 Risk
2 Rewards

Inogen, Inc. Key Details

US$354.3m

Revenue

US$196.6m

Cost of Revenue

US$157.7m

Gross Profit

US$182.3m

Other Expenses

-US$24.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.93
44.51%
-6.94%
0%
View Full Analysis

About INGN

Founded
2001
Employees
753
CEO
Kevin R. Smith
WebsiteView website
www.provider.inogen.com

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Recent INGN News & Updates

Analysis Article Aug 09

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67

Shareholders might have noticed that Inogen, Inc. ( NASDAQ:INGN ) filed its quarterly result this time last week. The...

Recent updates

No updates